Meeting
2023 ASCO Annual Meeting
Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo+Ipi): Results from the International mRCC Database Consortium (IMDC).
Authors
Audreylie Lemelin
Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada
Audreylie Lemelin , Kosuke Takemura , Matthew Scott Ernst , J Connor Wells , Frede Donskov , Camillo Porta , Guillermo de Velasco , Ian D. Davis , Lori Wood , Sumanta Kumar Pal , Aaron Richard Hansen , Christian K. Kollmannsberger , Georg A. Bjarnason , Ben Tran , Haoran Li , Ravindran Kanesvaran , Thomas Powles , Rana R. McKay , Toni K. Choueiri , Daniel Yick Chin Heng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4538)
DOI
10.1200/JCO.2023.41.16_suppl.4538
Abstract #
4538
Poster Bd #
30
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Multi-centre review of systemic anti-cancer prescribing patterns and treatment drop off rates in the United Kingdom 2018-2021.
First Author: John McGrane
Poster
2020 Genitourinary Cancers Symposium
A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab.
First Author: Landon Carter Brown
Poster
2018 Genitourinary Cancers Symposium
Optimizing axitinib treatment selection following first-line sunitinib in metastatic renal cell carcinoma.
First Author: Sergio Bracarda
Poster
2024 ASCO Genitourinary Cancers Symposium
Treatment patterns and costs among patients with metastatic renal cell carcinoma (mRCC) in the United States: A real-world study using integrated claims and clinical data.
First Author: Daniel M. Geynisman